Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 4, 2004, Pages 455-462

  Wong, W M ^a   Lai, K C ^a   Hui, W M ^a   Lam, K F ^a   Huang, J Q ^a   Hu, W H C ^a   Wong, N Y H ^a   Lam, C L K ^a   Xia, H H X ^a   Chan, A O O ^a   Lam, S K ^a   Wong, B C Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MALE; PH MEASUREMENT; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; CHINA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; TREATMENT OUTCOME;

EID: 10744232346     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2004.01846.x     Document Type: Article

References (23)

1. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999; 44(Suppl. 2): S1-16.
2. Goh KL, Chang CS, Fock KM, et al. Gastroesophageal reflux disease in Asia. J Gastroenterol Hepatol 2000; 15: 230-8.
3. Bell NJV, Gurget D, Howden ChW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion 1992; 59(Suppl. 1): 59-67.
4. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159: 649-57.
5. Locke GR 3rd, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
6. Wong WM, Lai KC, Lam KF, et al. Prevalence, clinical spectrum and health care utilisation of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther 2003; 18: 595-604.
7. Wong WM, Lam SK, Hui WM, et al. Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese -prevalence and spectrum of the disease. Aliment Pharmacol Ther 2002; 16: 2037-42.
8. Lam SK, Hasan M, Sircus W, Wong J, Ong GB, Prescott RJ. Comparison of maximal acid output and gastrin response to meals in Chinese and Scottish normal and duodenal ulcer subjects. Gut 1980; 21: 324-8.
9. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9.
10. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels. Aliment Pharmacol Ther 1999; 13: 1343-6.
11. Wong WM, Lam KF, Lai KC, et al. Validated symptoms questionnaire (Chinese-GERDQ) for the diagnosis of gastroesophageal reflux disease in a Chinese population. Aliment Pharmacol Ther 2003; 17: 1407-13.
12. Wong BCY, Wong WM, Wang WH, et al. An evaluation of invasive and non-invasive tests for the diagnosis of Helicobacter pylori infection in Chinese. Aliment Pharmacol Ther 2001; 15: 505-11.
13. Lam CLK, Gandek B, Ren XS, Chan MS. Tests of scaling assumptions and construct validity of the Chinese (HK) version of the SF-36 health survey. J Clin Epidemiol 1998; 51: 1139-47.
14. Hu WHC, Wong YH, Lai KC, et al. Normal 24-hour ambulatory proximal and distal gastroesophageal reflux parameters in Chinese. Hong Kong Med J 2002; 8: 168-71.
15. Hatlebakk JG. Review article: gastric acidity - comparison of esomeprazole with other proton pump inhibitors. Aliment Pharmacol Ther 2003; 17(Suppl. 1): 5.
16. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
17. Wong BCY, Lam SK, Ching CK, et al. Seroprevalence of cytotoxin- associated gene A positive Helicobacter pylori strains in Changle, an area with very high prevalence of gastric cancer in south China. Aliment Pharmacol Ther 1999; 13: 1295-302.
18. Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997; 24: 65-70.
19. Blum RA, Shi H, Karol MD, Greski-Rose PA, Hunt RH. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 1997; 19: 1013-23.
20. Röhss K, Clarr-Nilsson C, Rydholm H, Nyman L. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg. Gastroenterology 2000; 118: A20(Abstract).
21. Huang JQ, Goldwater DR, Thomson AB, et al. Acid suppression in healthy subjects following lansoprazole or pantoprazole. Aliment Pharmacol Ther 2002; 16: 425-33.
22. Johanson JF, Siddique R, Damiano AM, Jokubaitis L, Murthy A, Bhattacharjya A. Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease. Dig Dis Sci 2002; 47: 2574-8.
23. Pare P, Armstrong D, Pericak D, Pyzyk M. Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. J Clin Gastroenterol 2003; 37: 132-8.